Concepedia

Durvalumab Therapy

Durvalumab Therapy is a form of immune checkpoint inhibitor therapy that selectively targets the programmed death-ligand 1 (PD-L1) to enhance antitumor immune responses in the treatment of advanced hepatocellular carcinoma.

606

Publications

53.4K

Citations

6.2K

Authors

1.7K

Institutions

Publications per year

2017–2026

579

Parents

Publications

606

Durvalumab after Chemoradiotherapy in Stage III Non–Small-Cell Lung Cancer

Scott Antonia, Augusto Villegas, Davey B. Daniel et al. · New England Journal of Medicine · 2017 · 4.5K citations · Full text

, , +15

Overall Survival with Durvalumab after Chemoradiotherapy in Stage III NSCLC

Scott Antonia, Augusto Villegas, Davey B. Daniel et al. · New England Journal of Medicine · 2018 · 2.8K citations · Full text

, , +17

Durvalumab plus platinum–etoposide versus platinum–etoposide in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): a randomised, controlled, open-label, phase 3 trial

Luis Paz‐Ares, Mikhail Dvorkin, Yuanbin Chen et al. · The Lancet · 2019 · 2.2K citations

, , +14

Tremelimumab plus Durvalumab in Unresectable Hepatocellular Carcinoma

Ghassan K. Abou‐Alfa, George Lau, Masatoshi Kudo et al. · NEJM Evidence · 2022 · 1.4K citations · Full text

, , +16

Five-Year Survival Outcomes From the PACIFIC Trial: Durvalumab After Chemoradiotherapy in Stage III Non–Small-Cell Lung Cancer

Journal of Clinical Oncology · 2022 · 1.3K citations · Full text

, , +16

1–5 of 606

Authors

6.2K

  1. SA
    Scott Antonia

    Moffitt Cancer Center, United States

    34 publications · 11K citations

    26

    h-index

  2. MÖ
    Mustafa Özgüroğlu

    Istanbul University-Cerrahpaşa, Türkiye

    28 publications · 15.4K citations

    23

    h-index

  3. LP
    Luis Paz‐Ares

    Hospital Universitario 12 De Octubre, Spain

    27 publications · 12.7K citations

    21

    h-index

  4. NR
    Niels Reinmuth

    Asklepios Fachkliniken München-Gauting, Germany

    32 publications · 8.2K citations

    21

    h-index

  5. AG
    Ashok Gupta

    Post Graduate Institute of Medical Education and Research, India

    27 publications · 4K citations

    20

    h-index

1–5 of 6.2K

Institutions

1.7K

  1. AstraZeneca (United States)

    Wilmington, United States

    60 h-index

    491 publications

    53.8K citations

  2. AstraZeneca (United Kingdom)

    Cambridge, United Kingdom

    51 h-index

    312 publications

    39.4K citations

  3. Memorial Sloan Kettering Cancer Center

    New York, United States

    46 h-index

    344 publications

    26.8K citations

  4. Moffitt Cancer Center

    Tampa, United States

    36 h-index

    96 publications

    14.1K citations

  5. Institut Gustave Roussy

    Villejuif, France

    34 h-index

    114 publications

    26.4K citations

  6. The University of Texas MD Anderson Cancer Center

    Houston, United States

    33 h-index

    439 publications

    80.9K citations

  7. Sungkyunkwan University

    Seoul, South Korea

    33 h-index

    112 publications

    18.4K citations

  8. Samsung Medical Center

    Seoul, South Korea

    33 h-index

    115 publications

    10.4K citations

1–8 of 1.7K

Venues

  1. Journal of Clinical Oncology

    131 publications · 9K citations

    42

    h-index

  2. Journal of Thoracic Oncology

    39 publications · 2.9K citations

    27

    h-index

  3. Annals of Oncology

    54 publications · 3.2K citations

    26

    h-index

  4. Clinical Cancer Research

    25 publications · 1.7K citations

    23

    h-index

  5. Journal for ImmunoTherapy of Cancer

    JITC · 28 publications · 2.1K citations

    22

    h-index

1–5